Hua Medicine - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Chen Li, was filed 02 Dec 2025.
Hua Medicine - B: what insiders have been doing
Hua Medicine - B, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to HKEX. From 22 October 2025 to 22 October 2026, the disclosure feed for Hua Medicine - B logged 7 filings by 3 insiders.
The flow runs one way only: 3 insiders bought (3 purchases) and nobody sold on the market. The totals exclude 3 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 3 senior executives.
The latest purchase dates back some time: it was published 342 days ago, on 2 December 2025. The median gap between a trade and its publication by HKEX is 4 days. This delay matters because a trade only becomes useful information once it is public.
For context, the typical company on the same exchange (median of 1,314 companies) published 4 filings over the same period, against 7 filings here. Our records for Hua Medicine - B go back to 2018, with 16 purchases and no sales on the open market in total.
Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -31.9%Entry HK$2.32 · Close at T+365 HK$1.58
- +7.3%Entry HK$5.08 · Close at T+365 HK$5.45
- -3.6%Entry HK$5.23 · Close at T+365 HK$5.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 750,000 sharesShareXHKGHKEX:DA20260715E00535
- 1,375,000 sharesShareXHKGHKEX:DA20251231E00027
- 750,000 sharesShareXHKGHKEX:DA20251216E00062
- 3,400,000 sharesShareXHKGHKEX:DA20251202E00149Canonical exit: 26 Feb 2026 (T+90)
- 500,000 sharesShareXHKGHKEX:DA20251202E00156Canonical exit: 26 Feb 2026 (T+90)
- 900,000 sharesShareXHKGHKEX:DA20251202E00157Canonical exit: 26 Feb 2026 (T+90)
- 2,000,000 sharesShareXHKGHKEX:DA20251121E00136
- 3,000,000 sharesShareXHKGHKEX:DA20250402E00125Canonical exit: 26 Jun 2025 (T+90)
- 200,000 sharesShareXHKGHKEX:DA20250402E00144Canonical exit: 26 Jun 2025 (T+90)
- 210,000 sharesShareXHKGHKEX:DA20250402E00170Canonical exit: 26 Jun 2025 (T+90)
- 1,500,000 shares@ HK$0.546100.0% of flowShareXHKGHKEX:DA20250402E00169
- 200,000 sharesShareXHKGHKEX:DA20241119E00177
- 11,633,320 sharesShareXHKGHKEX:DA20240315E00225
- 1,200,000 sharesShareXHKGHKEX:DA20230406E00197Canonical exit: 29 Jun 2023 (T+90)
- 4,000,000 sharesShareXHKGHKEX:DA20230406E00198Canonical exit: 29 Jun 2023 (T+90)
- 1,059,000 shares@ HK$2.75895.4% of flowShareXHKGHKEX:DA20221014E00431Canonical exit: 11 Jan 2023 (T+90)
- 59,000 shares@ HK$2.3744.6% of flowShareXHKGHKEX:DA20221014E00429Canonical exit: 10 Jan 2023 (T+90)
- 154,613 sharesShareXHKGHKEX:DA20220915E00053
- 154,646 sharesShareXHKGHKEX:DA20220815E00106
- 154,646 sharesShareXHKGHKEX:DA20220715E00109
- 154,646 sharesShareXHKGHKEX:DA20220615E00084
- 154,646 sharesShareXHKGHKEX:DA20220516E00106
- 154,646 sharesShareXHKGHKEX:DA20220419E00268
- 5,000,000 sharesShareXHKGHKEX:DA20220322E00156Canonical exit: 15 Jun 2022 (T+90)
- 154,646 sharesShareXHKGHKEX:DA20220315E00082
25 of 82 declarations
About Hua Medicine - B
Hua Medicine is a biopharmaceutical company focused on developing innovative treatments for type 2 diabetes. It concentrates on the research and commercialization of drugs based on insulin pathway modulation.
